SINPAIN

The project:

Osteoarthritis is the most common chronic joint disorder worldwide, but there is no efficient treatment so far. Therefore, new medications are needed to improve the quality of life for those affected and reduce the high costs associated with this disease. Taking advantage of the explosion of RNA technologies in the last years, the SINPAIN project sets out to fill this gap by developing a safe, efficient and cost-effective small interfering RNA (siRNA)-based therapy combining RNA technology with improved intraarticular hyaluronic acid-based knee viscosupplement (IA-HA) containing tissue engineering tools, such as nanocarriers. Ultimately, the team aims to develop more personalised diagnostic and treatment options for different stages of osteoarthritis. Bringing together specialists from twelve partner institutions based in Europe and the US, SINPAIN receives a total funding of EUR 5,3 million from the Horizon Europe programme, starting May 2022 and over the next four and half years.

CIDETEC’S role in the project:

CIDETEC Nanomedicine is the coordinator of the project and leader of two WPs. CIDETEC will be responsible for the production of nanocarriers for siRNAs and antiinflamatory drugs, for the development of an improved dynamic hyaluronic acid to be used as viscosupplement and for the scaling-up and establishment of the production process. It will also have a leading role in the communication, dissemination and exploitation of results.